Perjeta (Pertuzumab) vs Enhertu (fam-trastuzumab deruxtecan-nxki)
Perjeta (Pertuzumab) vs Enhertu (fam-trastuzumab deruxtecan-nxki)
Perjeta (pertuzumab) is a monoclonal antibody designed to target the HER2 receptor, a protein overexpressed in some breast cancers, and is often used in combination with other therapies for the treatment of HER2-positive breast cancer. Enhertu (fam-trastuzumab deruxtecan-nxki), on the other hand, is an antibody-drug conjugate that combines a HER2-targeted antibody with a chemotherapy drug, allowing for the direct delivery of the chemotherapy to the cancer cells overexpressing HER2. The choice between Perjeta and Enhertu would depend on various factors including the specific characteristics of the cancer, prior treatments, and the patient’s overall health, and should be made in consultation with an oncologist who can evaluate the benefits and risks of each treatment in the context of the individual patient's medical history.
Difference between Perjeta and Enhertu
Metric | Perjeta (Pertuzumab) | Enhertu (fam-trastuzumab deruxtecan-nxki) |
---|---|---|
Generic name | Pertuzumab | Trastuzumab deruxtecan |
Indications | HER2-positive breast cancer | HER2-positive breast cancer, HER2-positive gastric cancer |
Mechanism of action | HER2/neu receptor antagonist | HER2-directed antibody and topoisomerase inhibitor conjugate |
Brand names | Perjeta | Enhertu |
Administrative route | IV infusion | IV infusion |
Side effects | Diarrhea, rash, nausea, fatigue, infusion reactions | Nausea, fatigue, vomiting, alopecia, constipation, decreased appetite |
Contraindications | Hypersensitivity to pertuzumab or its excipients | Hypersensitivity to trastuzumab deruxtecan or its excipients |
Drug class | Monoclonal antibody | Antibody-drug conjugate |
Manufacturer | Genentech (Roche) | Daiichi Sankyo and AstraZeneca |
Efficacy
Efficacy of Perjeta (Pertuzumab) in Breast Cancer
Perjeta (pertuzumab) is a monoclonal antibody that targets the HER2 receptor, a protein that can promote the growth of cancer cells. In the treatment of breast cancer, pertuzumab is specifically indicated for use in HER2-positive breast cancer, which is a subtype where cancer cells overexpress the HER2 protein. The efficacy of Perjeta in combination with trastuzumab and chemotherapy has been demonstrated in several clinical trials, including the CLEOPATRA study, which showed a significant improvement in progression-free survival and overall survival in patients with metastatic HER2-positive breast cancer. The addition of pertuzumab to standard therapy has been shown to enhance the anti-tumor activity, potentially leading to improved outcomes for patients.
Efficacy of Enhertu (fam-trastuzumab deruxtecan-nxki) in Breast Cancer
Enhertu (fam-trastuzumab deruxtecan-nxki) is an antibody-drug conjugate that combines a HER2-targeted antibody with a cytotoxic drug. It is approved for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The efficacy of Enhertu has been evaluated in pivotal trials such as the DESTINY-Breast01 trial, which demonstrated a significant response rate in patients treated with this drug. The results indicated substantial tumor shrinkage and a durable response, making Enhertu a valuable treatment option for patients with heavily pretreated HER2-positive metastatic breast cancer.
Comparative Efficacy in Different Settings
While both Perjeta and Enhertu are used in the treatment of HER2-positive breast cancer, their indications and use in the treatment timeline differ. Perjeta is often used in the early treatment setting, including the neoadjuvant (pre-surgery) setting, and in combination with first-line treatments for metastatic disease. In contrast, Enhertu is typically reserved for patients who have previously undergone multiple therapies, reflecting its role in treating more advanced stages of the disease. The choice between these agents depends on several factors, including the treatment line, patient characteristics, and previous therapies.
Conclusion
Both Perjeta and Enhertu have shown efficacy in improving outcomes for patients with HER2-positive breast cancer. Perjeta, in combination with other therapies, has been a standard treatment, particularly in the early and first-line metastatic settings. On the other hand, Enhertu has emerged as a powerful option for patients with advanced disease who have exhausted other treatments. The continued development and clinical evaluation of these targeted therapies offer hope for improved survival and quality of life for patients facing HER2-positive breast cancer.
Regulatory Agency Approvals
Perjeta
Enhertu
Access Perjeta or Enhertu today
If Perjeta or Enhertu are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us